These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 18976006

  • 21. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
    Tremosini S, Forner A, Boix L, Vilana R, Bianchi L, Reig M, Rimola J, Rodríguez-Lope C, Ayuso C, Solé M, Bruix J.
    Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
    [Abstract] [Full Text] [Related]

  • 22. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
    Zhang L, Liu H, Sun L, Li N, Ding H, Zheng J.
    Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
    [Abstract] [Full Text] [Related]

  • 23. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques.
    Shafizadeh N, Kakar S.
    Adv Anat Pathol; 2011 Nov; 18(6):438-45. PubMed ID: 21993269
    [Abstract] [Full Text] [Related]

  • 24. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
    Li J, Wei L.
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
    [Abstract] [Full Text] [Related]

  • 25. Liver biopsy for diagnosis of presumed benign hepatocellular lesions lacking magnetic resonance imaging diagnostic features of focal nodular hyperplasia.
    Sannier A, Cazejust J, Lequoy M, Cervera P, Scatton O, Rosmorduc O, Wendum D.
    Liver Int; 2016 Nov; 36(11):1668-1676. PubMed ID: 26969817
    [Abstract] [Full Text] [Related]

  • 26. MR imaging features for improved diagnosis of hepatocellular carcinoma in the non-cirrhotic liver: Multi-center evaluation.
    Fischer MA, Raptis DA, Donati OF, Hunziker R, Schade E, Sotiropoulos GC, McCall J, Bartlett A, Bachellier P, Frilling A, Breitenstein S, Clavien PA, Alkadhi H, Patak MA.
    Eur J Radiol; 2015 Oct; 84(10):1879-87. PubMed ID: 26194029
    [Abstract] [Full Text] [Related]

  • 27. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
    Scharitzer M, Schima W, Schober E, Reimer P, Helmberger TK, Holzknecht N, Stadler A, Ba-Ssalamah A, Weber M, Wrba F.
    J Comput Assist Tomogr; 2005 Oct; 29(2):181-90. PubMed ID: 15772534
    [Abstract] [Full Text] [Related]

  • 28. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.
    Yao S, Zhang J, Chen H, Sheng Y, Zhang X, Liu Z, Zhang C.
    J Histochem Cytochem; 2013 Sep; 61(9):639-48. PubMed ID: 23686365
    [Abstract] [Full Text] [Related]

  • 29. Diffuse and canalicular patterns of glypican-3 expression reflect malignancy of hepatocellular carcinoma.
    Kawaida M, Yamazaki K, Tsujikawa H, Fukuma M, Abe Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M.
    Pathol Int; 2019 Mar; 69(3):125-134. PubMed ID: 30729617
    [Abstract] [Full Text] [Related]

  • 30. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma.
    Joseph NM, Ferrell LD, Jain D, Torbenson MS, Wu TT, Yeh MM, Kakar S.
    Mod Pathol; 2014 Jan; 27(1):62-72. PubMed ID: 23807780
    [Abstract] [Full Text] [Related]

  • 31. p53 immunoreactivity in hepatocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular carcinoma.
    Ojanguren I, Ariza A, Castellà EM, Fernández-Vasalo A, Mate JL, Navas-Palacios JJ.
    Histopathology; 1995 Jan; 26(1):63-8. PubMed ID: 7713485
    [Abstract] [Full Text] [Related]

  • 32. Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis.
    Choi JY, Lee HC, Yim JH, Shim JH, Lim YS, Shin YM, Yu ES, Suh DJ.
    J Gastroenterol Hepatol; 2011 Jun; 26(6):1004-9. PubMed ID: 21251063
    [Abstract] [Full Text] [Related]

  • 33. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
    Tátrai P, Somorácz A, Batmunkh E, Schirmacher P, Kiss A, Schaff Z, Nagy P, Kovalszky I.
    Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
    [Abstract] [Full Text] [Related]

  • 34. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
    Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J.
    Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
    [Abstract] [Full Text] [Related]

  • 35. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study.
    Ligato S, Mandich D, Cartun RW.
    Mod Pathol; 2008 May; 21(5):626-31. PubMed ID: 18264086
    [Abstract] [Full Text] [Related]

  • 36. Diagnostic value of clusterin immunostaining in hepatocellular carcinoma.
    Li Y, Liu F, Zhou W, Zhang S, Chu P, Lin F, Wang HL.
    Diagn Pathol; 2020 Oct 14; 15(1):127. PubMed ID: 33054843
    [Abstract] [Full Text] [Related]

  • 37. Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.
    Choi WT, Ramachandran R, Kakar S.
    Hum Pathol; 2017 May 14; 63():1-13. PubMed ID: 28087475
    [Abstract] [Full Text] [Related]

  • 38. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver.
    Levy M, Trivedi A, Zhang J, Miles L, Mattis AN, Kim GE, Lassman C, Anders RA, Misdraji J, Yerian LM, Xu H, Dhall D, Wang HL.
    Hum Pathol; 2012 May 14; 43(5):695-701. PubMed ID: 21937079
    [Abstract] [Full Text] [Related]

  • 39. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P.
    J Gastroenterol Hepatol; 2010 Jan 14; 25(1):129-37. PubMed ID: 19793164
    [Abstract] [Full Text] [Related]

  • 40. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
    Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T.
    Int J Oncol; 2009 Mar 14; 34(3):649-56. PubMed ID: 19212669
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.